FY24 has come to a close, marking a year of stark contrasts for many investors. The year began on shaky ground, with markets enduring a particularly challenging period in September and October. However, as the year progressed, we managed to close on a relatively positive note.
The market's turnaround began to take shape in the December quarter, giving rise to several prominent themes. Among these were the widespread adoption of AI technologies, a resurgence in commodities (notably gold, silver, and uranium) and renewed interest in the biotech sector.
Below, we'll spotlight some of the top-performing stocks across various indices, including the ASX 20, ASX Midcap 50, ASX 200, and All Ordinaries.
Goodman Group claims the top spot, a position that comes as no surprise given its leverage to the AI boom. The company's trajectory shifted dramatically during the February reporting season, which served as a pivotal catalyst for the stock's performance. The result topped first-half earnings expectations, upgraded its full-year guidance and revealed that data centres now represent over a third of its work-in-progress pipeline.
Ticker | Company | Close | 1 Year |
---|---|---|---|
Goodman Group | $34.75 | 73.8% | |
National Australia Bank | $36.23 | 37.7% | |
Wesfarmers | $65.18 | 33.4% | |
Aristocrat Leisure | $49.76 | 29.5% | |
Westpac Banking | $27.23 | 27.1% |
Pro Medicus experienced a remarkable run in FY24, though not without its share of challenges. The company faced a significant setback post-February reporting season, with the stock suffering a 20% drawdown as results fell short of lofty market expectations. Despite the softer-than-anticipated performance, analysts remained bullish, projecting that Pro Medicus is well-positioned to double its market share over the next five years. The stock quickly rebounded, recouping its losses over the subsequent two months. Pro Medicus closed out FY24 on a high note, with its share price reaching all-time highs.
Ticker | Company | Close | 1 Year |
---|---|---|---|
Pro Medicus | $143.26 | 114.7% | |
Altium | $68.03 | 86.0% | |
Seven Group | $37.68 | 53.2% | |
Car Group | $35.25 | 49.8% | |
NextDC | $17.63 | 44.2% |
Life360, the family social media app developer, emerged as a growth powerhouse in FY24. The company's stock soared nearly 40% in a single day on March 1, following a better-than-expected full-year 2023 report and upgraded 2024 guidance. Life360's successful Nasdaq listing opened doors to potential US capital raising and potentially a higher valuation.
Ticker | Company | Close Price | 1 Year |
---|---|---|---|
Life360 | $16.37 | 123.6% | |
Pro Medicus | $143.26 | 114.7% | |
Red 5 | $0.36 | 89.5% | |
West African Resources | $1.61 | 88.3% | |
Altium | $68.03 | 86.0% | |
Hub24 | $46.55 | 84.4% | |
Deep Yellow | $1.34 | 83.5% | |
Goodman Group | $34.75 | 73.8% | |
Siteminder | $5.09 | 71.6% | |
Neuren Pharmaceuticals | $21.27 | 70.8% |
Droneshield is a market leader and early mover in the counter-drone space – a market worth in excess of US$10 billion, according to Shaw and Partners. "The conflicts in Ukraine and the Middle East provide a case study on the evolution of warfare. We expect DRO to experience considerable operating leverage due to rising global defence budgets and a focus on counter-drone technology," the analysts said in a note last month. Droneshield is forecast to deliver around $103 million in sales for FY24, up 90.7% year-on-year.
Ticker | Company Name | Close Price | 1 Year |
---|---|---|---|
Droneshield | $1.72 | 681.4% | |
Clarity Pharmaceuticals | $5.42 | 629.7% | |
Spartan Resources | $0.99 | 483.1% | |
Nuix | $3.08 | 262.3% | |
Zip Co | $1.46 | 256.1% | |
WA1 Resources | $19.28 | 221.3% | |
Botanix Pharmaceuticals | $0.35 | 213.6% | |
Superloop | $1.61 | 174.3% | |
Ora Banda Mining | $0.34 | 168.0% |
Get the latest news and insights direct to your inbox